AAAAAA
Results:
1-21
|
Results: 21
Authors:
Mathijssen, RHJ
van Alphen, RJ
Verweij, J
Loos, WJ
Nooter, K
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), CLIN CANC R, 7(8), 2001, pp. 2182-2194
Authors:
Gelderblom, H
Verweij, J
Nooter, K
Sparreboom, A
Citation: H. Gelderblom et al., Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, EUR J CANC, 37(13), 2001, pp. 1590-1598
Authors:
de Jongh, FE
Verweij, J
Loos, WJ
de Wit, R
de Jonge, MJA
Planting, AST
Nooter, K
Stoter, G
Sparreboom, A
Citation: Fe. De Jongh et al., Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure, J CL ONCOL, 19(17), 2001, pp. 3733-3739
Authors:
van Zuylen, L
Karlsson, MO
Verweij, J
Brouwer, E
de Bruijn, P
Nooter, K
Stoter, G
Sparreboom, A
Citation: L. Van Zuylen et al., Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles, CANC CHEMOT, 47(4), 2001, pp. 309-318
Authors:
Sparreboom, A
Nooter, K
Loos, WJ
Verweij, J
Citation: A. Sparreboom et al., The (ir)relevance of plasma protein binding of anticancer drugs, NETH J MED, 59(4), 2001, pp. 196-207
Authors:
Schenk, PW
Boersma, AWM
Brandsma, JA
den Dulk, H
Burger, H
Stoter, G
Brouwer, J
Nooter, K
Citation: Pw. Schenk et al., SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line, CANCER RES, 61(19), 2001, pp. 6982-6986
Authors:
Loos, WJ
Kehrer, D
Brouwer, E
Verweij, J
de Bruijn, P
Hamilton, M
Gill, S
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography, J CHROMAT B, 738(1), 2000, pp. 155-163
Authors:
Sparreboom, A
Nooter, K
Citation: A. Sparreboom et K. Nooter, Does P-glycoprotein play a role in anticancer drug pharmacokinetics?, DRUG RESIST, 3(6), 2000, pp. 357-363
Authors:
van Zuylen, L
Verweij, J
Nooter, K
Brouwer, E
Stoter, G
Sparreboom, A
Citation: L. Van Zuylen et al., Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans, CLIN CANC R, 6(7), 2000, pp. 2598-2603
Authors:
van Zuylen, L
Nooter, K
Sparreboom, A
Verweij, J
Citation: L. Van Zuylen et al., Development of multidrug-resistance convertors: sense or nonsense?, INV NEW DR, 18(3), 2000, pp. 205-220
Authors:
Burger, H
Capello, A
Schenk, PW
Stoter, G
Brouwer, J
Nooter, K
Citation: H. Burger et al., A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin, BIOC BIOP R, 269(3), 2000, pp. 767-774
Authors:
Loos, WJ
de Bruijn, P
van Zuylen, L
Verweij, J
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Determination of 5-fluorouracil in microvolumes of human plasma by solventextraction and high-performance liquid chromatography, J CHROMAT B, 735(2), 1999, pp. 293-297
Authors:
Sparreboom, A
Loos, WJ
Nooter, K
Stoter, G
Verweij, J
Citation: A. Sparreboom et al., Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel, J CHROMAT B, 735(1), 1999, pp. 111-119
Authors:
Sparreboom, A
Planting, AST
Jewell, RC
van der Burg, MEL
van der Gaast, A
de Bruijn, P
Loos, WJ
Nooter, K
Chandler, LH
Paul, EM
Wissel, PS
Verweij, J
Citation: A. Sparreboom et al., Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein, ANTI-CANC D, 10(8), 1999, pp. 719-728
Authors:
Mathijssen, RHJ
van Alphen, RJ
de Jonge, MJA
Verweij, J
de Bruijn, P
Loos, WJ
Nooter, K
Vernillet, L
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin, ANTI-CANC D, 10(1), 1999, pp. 9-16
Authors:
Sparreboom, A
De Jonge, MJA
Punt, CJA
Loos, WJ
Nooter, K
Stoter, G
Porro, MG
Verweij, J
Citation: A. Sparreboom et al., Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis, DRUG META D, 27(7), 1999, pp. 816-820
Disposition of [G-H-3]paclitaxel and cremophor EL in a patient with severely impaired renal function
Authors:
Gelderblom, H
Verweij, E
Brouwer, E
Pillay, M
De Bruijn, P
Nooter, K
Stoter, G
Sparreboom, A
Citation: H. Gelderblom et al., Disposition of [G-H-3]paclitaxel and cremophor EL in a patient with severely impaired renal function, DRUG META D, 27(11), 1999, pp. 1300-1305
Authors:
Burger, H
Nooter, K
Boersma, AWM
van Wingerden, KE
Looijenga, LHJ
Jochemsen, AG
Stoter, G
Citation: H. Burger et al., Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines, INT J CANC, 81(4), 1999, pp. 620-628
Authors:
Sparreboom, A
van Zuylen, L
Brouwer, E
Loos, WJ
de Bruijn, P
Gelderblom, B
Pillay, M
Nooter, K
Stoter, G
Verweij, J
Citation: A. Sparreboom et al., Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications, CANCER RES, 59(7), 1999, pp. 1454-1457
Authors:
de Bruijn, P
de Jonge, MJA
Verweij, J
Loos, WJ
Nooter, K
Stoter, G
Sparreboom, A
Citation: P. De Bruijn et al., Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography, ANALYT BIOC, 269(1), 1999, pp. 174-178
Authors:
de Bruijn, P
Verweij, J
Loos, WJ
Kolker, HJ
Planting, AST
Nooter, K
Stoter, G
Sparreboom, A
Citation: P. De Bruijn et al., Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography, ANALYT BIOC, 266(2), 1999, pp. 216-221
Risultati:
1-21
|